Stocktoria
Artiva Biotherapeutics, Inc. ARTV
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-07-19
Artiva Biotherapeutics, Inc. financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $0 | $251,000 | $33.5M |
| R&D expense | $69.5M | $50.3M | $50.3M |
| Operating income | -$89.8M | -$67.3M | -$30.7M |
| Income tax | $0 | $0 | $72,000 |
| Net income | -$83.9M | -$65.4M | -$28.7M |
| EPS (diluted) | $-3.43 | $-5.81 | $-35.78 |
| Operating cash flow | -$76.8M | -$55.0M | -$47.4M |
| Free cash flow | -$79.3M | -$55.7M | -$50.7M |
| Cash & equivalents | $26.7M | $40.2M | $53.5M |
| Total assets | $130.9M | $209.6M | $105.1M |
| Total liabilities | $21.0M | $22.9M | $50.7M |
| Shareholders' equity | $110.0M | $186.6M | -$162.0M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue growth | -100.0% | -99.3% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.